Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia ...

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five instituti...
Streetwise Reports | February 3, 2020 |

3 reasons to avoid penny stocks

A Note From the Editorial Director: This week, with the first installment of our new Member Mailbag feature, we start putting the You in Investment U. The Mailbag gives you the chance to ask Alex Green and our other investment experts about the financial subjects that are o...
Alexander Green | August 27, 2013 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Buzz on the Bullboards: Creating Cash out of an Economy Crunch

(Image via Bombardier Inc.) If you’re looking to see the stocks that investors have been keeping an eye on over the past week, you’ve come to the right place. The Stockhouse community regularly acts as a microcosm of investor sen...
Stockhouse Editorial | May 25, 2022 |

Danavation Technologies rapidly expands across North America

TMH: Driven by cutting-edge IoT automation technology and proprietary software, Danavation Technologies is the only electronic shelf label provider grounded and based in North America. The company has noted rapid expansion across Canada and the United States, providing c...
Brieanna McCutcheon | June 20, 2023 |

Jackpot Digital (TSXV:JJ): Meet the company revolutionizing casino gaming

What does the future of casino gaming look like? Well, just imagine, for a moment, being on a cruise, playing the tables at the casino, and you hit a patch of rough waters. Well, Jackpot Digital, it seems, has thought of this. They signed a deal in 2017 with Carni...
Brieanna McCutcheon | November 14, 2022 |

Cannabis tester FluroTech is a market disruptor

The legalization of cannabis in Canada - only the second country after Uruguay to do so - presents a huge business opportunity here and elsewhere. The global cannabis market is expected to hit $146 billion by the end of 2025. Most of the action is expected to be centered in ...
Richard (Rick) Mills | March 20, 2019 |

FluroTech provides Licensed Producer’s rapid and effective inhouse cannabis testing

Imagine walking into your local liquor store to pick up a bottle of wine. You have a few favorite varietals in mind, but you don’t trust the alcohol percentages you see on the labels. Last week you bought a Cabernet-Sauvignon from Chile, supposedly 14% alcoho...
Richard (Rick) Mills | July 3, 2019 |